[{"id":"d4a8f858-34d0-4450-b14d-4588fe783648","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687110","created_at":"2023-01-18T15:59:52.715Z","updated_at":"2025-02-25T16:54:40.188Z","phase":"Phase 1","brief_title":"Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes","source_id_and_acronym":"NCT05687110","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-04"},{"id":"288f7dec-e867-48c2-b680-c85e10373a85","acronym":"SYN-818-101","url":"https://clinicaltrials.gov/study/NCT06666270","created_at":"2025-02-26T15:17:14.611Z","updated_at":"2025-02-26T15:17:14.611Z","phase":"Phase 1","brief_title":"Phase I Study of SYN818 Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06666270 - SYN-818-101","lead_sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-10-30"},{"id":"80d058fa-b19a-4e22-b59d-ca59b8425b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04991480","created_at":"2021-08-05T13:53:03.393Z","updated_at":"2024-07-02T16:34:59.371Z","phase":"Phase 1","brief_title":"A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04991480","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Zejula (niraparib) • ART4215"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-03"},{"id":"e381b221-6768-4bcf-80c5-d9caedaede97","acronym":"","url":"https://clinicaltrials.gov/study/NCT05898399","created_at":"2023-06-12T16:09:01.959Z","updated_at":"2024-07-02T16:35:01.189Z","phase":"Phase 1/2","brief_title":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients","source_id_and_acronym":"NCT05898399","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • ART6043"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 05/14/2026","primary_completion_date":" 05/14/2026","study_txt":" Completion: 12/14/2026","study_completion_date":" 12/14/2026","last_update_posted":"2024-05-24"}]